DFTX
NasdaqGSDefinium Therapeutics, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 10 recent filings. 5 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Sullivan Mark Chief Legal Officer | Sell (open market) | 13.01K | $45.03 | $585,750.24 | 2026-06-25 |
Roberts Brandi Chief Financial Officer | Sell (open market) | 3.01K | $45.03 | $135,675.39 | 2026-06-25 |
Barrow Robert Director, Chief Executive Officer | Sell (open market) | 29.21K | $45.03 | $1,315,236.24 | 2026-06-25 |
Karlin Daniel Chief Medical Officer | Sell (open market) | 10.04K | $45.03 | $451,876.05 | 2026-06-25 |
Wiley Matthew T. Chief Commercial Officer | Sell (open market) | 2.87K | $45.03 | $129,101.01 | 2026-06-25 |
Wiley Matthew T. Chief Commercial Officer | Grant / award | 62.5K | $0.00 | — | 2026-06-22 |
Barrow Robert Director, Chief Executive Officer | Grant / award | 375K | $0.00 | — | 2026-06-22 |
Roberts Brandi Chief Financial Officer | Grant / award | 62.5K | $0.00 | — | 2026-06-22 |
Sullivan Mark Chief Legal Officer | Grant / award | 62.5K | $0.00 | — | 2026-06-22 |
Karlin Daniel Chief Medical Officer | Grant / award | 100K | $0.00 | — | 2026-06-22 |
Source: SEC EDGAR Forms 4/4A (CIK 1813814). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
@Millionaire11 it isn't even the main selling point for $DFTX, just a bonus ;) All i'm hearing from CMPS folks can be summarized like this "waaa waaa, my younger brother excels at Football and Basketball, but I'm only good at Basketball, why did he get a scholarship for Basketball?!? life isn't fair😭" quit whining and complaining, your time will come, just be patient.
@Millionaire11 Lycos was denied FDA approval due to non-ethical trial designs. $DFTX will be fine.
@Millionaire11 mushrooms work and $CMPS will still be a great play, but LSD will be shown to shake its stigma. $DFTX just will have the suspense headlines. It will bode well for both in the very near term.
@twiggs462 it will be $CMPS first mover advantage. News headlines will not be $DFTX
$CMPS $DFTX
@leLu83 average retail price is roughly 6.90 for ATAI, very small gains. YTD gains would be roughly 70%. Still good. $DFTX average retail price is 37.80. Already great gains. YTD is 230%. You might be able to fool 3rd graders with your comments but unfortunately for you most users here are grown adults that can do math. Not to mention ATAI gains are maxed out and capped. DFTX is just beginning!
$DFTX tell me you already spent that tiny ATAI payout, without telling me 🤣 get ready to see how it’s done my sad bro…
I personally think $ATAI sold becuase they know that cannot compete with $DFTX or $CMPS short term. Those two are going to take the spotlight and investors and $ATAI would have run out of money. I bet $LLY will take BPL-003 to market, but $ATAI would have not been able to
$DFTX will be the darling in the space. it will soon be front page news.
$DFTX investors from 2021 still in the Red 😂
$DFTX $CMPS Worth reading. https://www.psychologytoday.com/ca/blog/addiction-outlook/202607/how-can-a-drug-lasting-hours-change-the-brain-for-months
$ATAI word salad for "I needed the money" https://christianangermayer.substack.com/p/my-love-letter-to-psychedelics-and $DFTX $CMPS $HELP $GHRS
Latest news
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?
The Race to Commercialize the World’s Most Powerful Psychedelic
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
Leaderboard Quarterly Scorecard Webinar Q&A Summary For Thursday, July 9, 2026
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Definium Therapeutics Closes Public Offering of Common Shares
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.